Korglutide

Korglutide is a next-generation oral peptide composed of 7 amino acids, developed by Caregen as a nutraceutical solution for weight management and metabolic balance. Designed for once-daily intake, it offers a convenient non-invasive alternative to injectable approaches, supporting long-term adherence in preventive health management. As a food supplement, Korglutide supports targeted fat reduction and metabolic balance beyond simple weight loss. Notably, Korglutide completed the U.S. FDA New Dietary Ingredient (NDI) notification in January 2026, supporting its global regulatory positioning and reinforcing its safety profile. <Clinical Results> - In a randomized, double-blind, placebo-controlled Phase III study in obese individuals (BMI ≥ 30) and overweight individuals with type 2 diabetes (BMI ≥ 27), Korglutide demonstrated significant improvements across key metabolic parameters. Body weight decreased by -10.78% (-9.3 kg), BMI by -10.83%, HbA1c by -10.98%, WHR by -5.21%, and body fat mass by -20.71% (-7.0 kg), while skeletal muscle mass reduction remained limited to -0.75% (-0.27 kg), indicating fat reduction with minimized muscle loss (muscle ratio increased by 11.40%). - A second Phase III study in non-obese individuals including NWO (Normal Weight Obesity) showed -8.02% (-5.2 kg) reduction in body weight and -8.26% reduction in BMI, with body fat decreased by -9.6% and visceral fat level reduced by -9.21%, supporting improved body composition. These results indicate that Korglutide supports fat reduction while preserving lean mass across both obese and non-obese populations, positioning it as a body recomposition and metabolic wellness solution. Korglutide targets overweight, obese, visceral fat, and NWO populations, while also appealing to health-conscious consumers focused on body composition management. With a structured 12-week usage protocol, it offers a clinically supported solution aligned with growing demand for non-invasive health management.